Lexicon Pharmaceuticals to Host 2024 Investor Day
April 18, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the...
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner,...
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
March 25, 2024 09:20 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
March 12, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial...
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
March 11, 2024 07:15 ET
|
Lexicon Pharmaceuticals, Inc.
Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase...
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
March 11, 2024 07:05 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase...
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
March 11, 2024 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
Preparations Underway for Resubmission of New Drug Application for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in Patients with Type 1 Diabetes and Chronic Kidney Disease ...
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
-INPEFA® Launch Positioned for Acceleration in 2024- -Clinical Data and FDA Feedback Support INPEFA Life Cycle Management Opportunity in Hypertrophic Cardiomyopathy- ...
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
December 21, 2023 16:15 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 42nd Annual JPMorgan Healthcare Conference taking place...
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
November 30, 2023 07:30 ET
|
Lexicon Pharmaceuticals, Inc.
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...